The @ProsperTrial investigates a new type of personalised care planning, which is designed to improve patients’ self-management skills and wellbeing.

LOTUS is an international follow up study for patients with breast cancer who have previously taken part in the BEATRICE breast cancer trial.

The ALPHA trial compares Alitretinoin and PUVA therapy in patients aged 18 years and over with severe hand eczema.

We are interested to see whether the drug, ondansetron, can improve symptoms of diarrhoea in patients with irritable bowel syndrome.

EMT2 tests whether an omega-3 fatty acid (eicosapentaenoic acid, or EPA) improves outcomes in surgeries to remove bowel cancer that has spread to the liver.

The aims of the HERO trial are to establish the clinical and cost effectiveness of the HOPE programme compared to usual care.

PRISM is investigating the optimum schedule in which ipilimumab and nivolumab should be administered in order to give the best results for patients.

NET-02 is looking at different second-line treatment options for patients with poorly differentiated, extra-pulmonary neuroendocrine cancer.

PLATO is an umbrella trial incorporating 3 individual anal cancer trials and aims to optimise radiotherapy dose across the spectrum of disease.

FLAIR is a high-recruiting, randomised, clinical trial studying the treatment of Chronic lymphocytic leukaemia (CLL).

RETAKE is a national study which assesses the effectiveness of specific vocational rehabilitation in stroke survivors compared to generic rehabilitation.

The APHRODITE study aims to assess whether a higher radiotherapy dose is effective in the eradication of early stage rectal cancer.

MIDFUT is a study finding out the best way to treat diabetic foot ulcers (DFUs).

FiTNESS will be looking at a newer therapy drug called Ixazomib alongside older treatments to find potential benefits in the treatment of myeloma in older patients.

CODIFI2 compares two wound sample collection techniques (swab and tissue sampling) in clinically infected diabetic foot ulcer (DFU) patients.

NEPTUNE is investigating the effectiveness of radium-223 combined with an immunotherapy drug at treating breast cancer that has spread to the bones, compared to immunotherapy alone

RADAR (Myeloma XV) is a clinical trial that investigates precision medicine, based on the genetics of their myeloma and response to treatment.

ReoGlio is investigating the use of a virus in combination with other treatments for treating glioblastoma, a type of brain cancer.